Abstract
Introduction

Acute myeloid leukaemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of clonal neoplastic haematopoietic precursor cells and impaired production of normal haematopoiesis leading to neutropenia, anaemia and thrombocytopenia
. The 5 year survival rate of AML patients has remained at 20-30% since the 1970s [2] . The outcome for AML patients depends on a variety of factors, including the age of the patient, the intensity of post-remission therapy and the biological characteristics of the disease [3] [4] [5] . Thus there remains a need for rational, minimally toxic but effective therapies for AML [6] . [7] [8] [9] . This facilitates caspase- 8 [10, 11] .
Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promiscuous cytokine with the ability to bind to five different receptors. TRAIL-R1 death receptor (DR)4 and TRAIL-R2 (DR5), the two apoptosis-inducing TRAIL receptors, contain a conserved cytoplasmic death domain motif that undergoes a conformational change upon binding of TRAIL and results in the recruitment of the adaptor molecule Fas-associated via death domain (FADD)
recruitment and activation, which activates the apoptotic machinery. Decoy receptor 1 (DcR1/TRAIL-R3), decoy receptor 2 (DcR2/TRAIL-R4) and the soluble receptor osteoprotegerin lack or have a truncated cytoplasmic death domain and thus these receptors act to prevent apoptosis by sequestering available TRAIL or by interfering with the formation of a DR4 or DR5 signalling complex
A number of haematological malignancies are sensitive to TRAIL either as a single agent or in combination with chemotherapeutics [12] [13] [14] . Chronic lymphocytic leukaemia (CLL) cells undergo TRAIL-induced apoptosis by activation of DR4 rather than DR5 [15] , contrasting with the suggestion that DR5 may contribute more than DR4 to TRAIL-induced apoptosis in cancer cells expressing both TRAIL receptors [16] . Furthermore, primary mantle cell lymphoma cells were also found to be sensitive to TRAIL and similar to CLL cells, the TRAIL-death signal was almost exclusively transmitted through DR4 [12] . Interestingly, a study of 72 primary AML blasts revealed that while many AML blasts expressed DR4 (48.6%) and DR5 (12.5%) , the AML cells generally showed low sensitivity to TRAIL [17] .
A number of mechanisms have been associated with TRAIL resistance in AML. It has been suggested that high levels of decoy receptors were associated with TRAIL insensitivity [17] . [18] . [19] . Therefore based on these observations, we suggested that by increasing the affinity of TRAIL for DR4 a higher efficacy may be achieved, thus making engineered TRAIL suitable for the treatment of AML and other haematological malignancies.
Overexpression of cellular FADD-like Interleukin-1 converting enzyme (ICE)-like inhibitory protein (c-FLIP) has been reported as another mechanism of resistance of AML cells to TRAIL
High c-FLIP expression has also been recently reported to be linked to inferior outcome in AML patients with normal karyotype and intermediate risk
Experimental procedures
Site-directed mutagenesis, expression and purification of rhTRAIL variants
Construction and purification of wild-type (WT) TRAIL and variants was performed as described before [20] . The amino acid alterations in rhTRAIL-C3 did not change the homotrimeric structure of the molecule as the gel filtration elution profile of the mutant was not different from that of WT rhTRAIL (Fig. S2) .
Determination of receptor binding by surface plasmon resonance (SPR)
Binding experiments were performed with a SPR-based biosensor Biacore 3000 (GE Healthcare, Munich, Germany 
Western blotting
Polyacrylamide gel electrophoresis and Western blotting was carried out as previously described [22] . 
Results
Design and biochemical characterization of rhTRAIL-C3
Although approximately 50% of AMLs express at least one deathinducing TRAIL receptor on the cell surface, AML blasts display a low sensitivity to TRAIL [17] . In AML blasts, TRAIL fails to activate pro-caspase-8, indicating that inadequate receptor activation by TRAIL may be the cause of the low sensitivity [17] . Since DR4 is more frequently expressed on AML blasts than DR5, it was suggested that a high affinity, DR4-selective TRAIL variant would be able to trigger AML cell apoptosis. [24, 25] Fig. S4E ). In summary, rhTRAIL-C3 has a higher affinity for DR4 and a moderate increase in affinity for DcR1. The binding preference of the variant to DR5 and DcR2 remained unchanged. (Fig. S1A) and EM-2 (Fig. S1B) cells, but not A2780 cells (Fig. S1C) (Fig. 2A, B and D) . However, rhTRAIL-C3 failed to kill ⌬CT-DR4-BJAB cells, confirming its DR4-selective pro-apoptotic action (Fig. 2C) . This was reflected in the ED50 values, as it stayed nearly unchanged in WT, GFP and ⌬CT-DR5 cells, but increased by 13.49-fold in the ⌬CT-DR4 cells (Fig. 2) . WT-rhTRAIL on the other hand showed a 2.94-fold increase in the ED50 value on ⌬CT-DR5 BJAB cells and a 10.38-fold increase on the ⌬CT-DR4 cells, indicating its dual specificity towards DR4 and DR5 (Fig. 2) . [28] [29] [30] [31] . All four cell lines express both DR4 and DR5 on their surface (Fig. 3) .
In the search for an rhTRAIL variant that can efficiently induce apoptosis in AML blasts, we have combined mutation D218H (replacement of the aspartate at position 218 to histidine) with mutation G131R (glycine at position 131 to arginine) that, respectively, reduces the affinity of TRAIL to DR5 [23] or increases the apoptotic potential of rhTRAIL (Reis et al.). However, combination of G131R with D218H did not result in higher biological activity compared to WT rhTRAIL (Fig. S1). Scanning the receptor binding interface of TRAIL with the protein design algorithm FoldX
rhTRAIL-C3 is a potent inducer of apoptosis in AML
Cells were treated with 10-250 ng/ml of WT rhTRAIL, rhTRAIL-C3 or D269H/E195R (DR5-selective TRAIL variant) for 24 hrs and induction of apoptosis was quantified with annexin V staining. rhTRAIL-C3 appeared to be a much more potent apoptosisinducer than WT rhTRAIL in HL-60, ML-1 and MOLM13 cells (Fig. 4) . Like WT rhTRAIL, rhTRAIL-C3 could not induce apoptosis in OCI-AML3 cells (Fig. 4D) . OCI-AML3 cells are completely resistant to TRAIL (Fig. 4) [20, 32] .
We have previously reported that in ML-1 cells only DR4 is functional [20] . The functionality of DR4 and DR5 in HL-60, ML-
1, MOLM-13, OCI-AML3 and EM-2 cells was determined using agonistic anti-DR4 and anti-DR5 antibodies (Novartis). The cells were treated with 5-20 nM of the agonistic antibodies with or without previous crosslinking of the antibodies through their Fc region using a secondary antibody. After 24 hrs of treatment, induction of apoptosis was determined with 7-AAD staining. Results demonstrated that in HL-60, ML-1 and EM-2 cells DR4
Fig. 2. Deficiency of DR4 blocks rhTRAIL-C3 induced apoptosis. WT BJAB cells (A), BJAB cells overexpressing GFP (B), non-functional, C-terminal deletion mutants of DR4 (C) or DR5 (D) were treated with WT rhTRAIL and rhTRAIL-C3. Induction of apoptosis was determined by measuring loss of mitochondrial membrane potential (⌬⌿m).
was the primary mediator of TRAIL-induced apoptosis (Fig. 5A, Fig. 5C and D) . (Fig. 6A) . The stronger and faster DR4 activation by rhTRAIL-C3 was also reflected by the pattern of IB␣ phosphorylation and resulting degradation (Fig. 6B) . Fig. 4 ), but it also required only 14 min. to reach its half-maximal effect, while WT rhTRAIL required 73 min. for the same (Fig. 6C) . [18, 33] . Accordingly, inhibition of NF-B have been shown to restore TRAIL sensitivity in a range of tumour types [34, 35] (Fig. S5) .
B and E), in OCI-AML3 cells signalling through DR4 and DR5 was blocked and in MOLM-13 cells, while both receptors were functional, DR5 required activation using a tetravalent, crosslinked antibody (
To examine whether the high affinity of rhTRAIL-C3 enhanced DR4 activation, HL-60 cells, which have defective DR5 signalling, were selected. Two apical events of DR activation, i.e. procaspase-8 activation and NF-B activation were monitored over time as a measure of DR4 activation. Cells were treated with 100 ng/ml of WT rhTRAIL or rhTRAIL-C3 for 5-120 min. Cells were then harvested for detection of pro-caspase-8 processing into its active fragments, phosphorylation and degradation of IB␣. To examine the kinetics of apoptosis induction, as another measure or receptor activation, at the end of the incubation time the unbound ligands were removed from the cells by a wash step and the cells were resuspended in normal growth medium. The cells were then further incubated in total for 12 hrs to allow the execution of the apoptotic programme. As a positive control, ligands were left on the cells for 12 hrs. rhTRAIL-C3 induced earlier and stronger processing of procaspase-8 than WT rhTRAIL, indicating faster and more efficient DR4 activation by the TRAIL variant
The faster and more robust receptor activation induced by rhTRAIL-C3 was finally mirrored in the level and kinetics of apoptosis induction (Fig. 6C). rhTRAIL-C3 did not only induce higher level of cell death than WT rhTRAIL (67% and 53%, respectively, for full dosage please refer to
Fig. 3. Cell surface expression of TRAIL receptors in OCI-AML3, HL-60 and MOLM-13 cells. Cell surface expression of DR4, DR5, DcR1 and DcR2 was measured by immunostaining and detected with flow cytometry (FacsCanto II, Beckton Dickinson). The histograms are representatives of three independent experiments. Red filled peaks: isotype control, green open peaks: TRAIL receptor stained sample.
rhTRAIL-C3 is a potent inducer of apoptosis in primary AML blasts
To test whether rhTRAIL-C3 is a more potent apoptosis inducer than WT rhTRAIL in AML, primary AML blasts were analyzed for TRAIL receptor expression and sensitivity to WT rhTRAIL or rhTRAIL-C3, alone or in combination with the inhibitor B kinase (IKK) inhibitor, BMS-345541. NF-B has been shown to regulate the expression of a number of anti-apoptotic genes, including cellular FADD-like Interleukin-1 converting enzyme (FLICE)-inhibitory protein (c-FLIP) and XIAP, two molecules that have been associated with TRAIL resistance of AML and other tumour types
. Further supporting the viability of the combination of an NF-B inhibitor and TRAIL, we have found that HL-60 cells can be greatly sensitized to TRAIL by simultaneous inhibition of NF-B activation
Most samples expressed the TRAIL receptor at a detectable level, and many displayed a high level of decoy receptor (Table 2) expression. The clinical information of the analyzed samples is summarized in Table 3 . As expected, the AML samples had generally low TRAIL sensitivity (Fig. 7A) . However, analysis of the samples that showed some level of TRAIL sensitivity revealed that rhTRAIL-C3 had a significantly higher pro-apoptotic activity than WT rhTRAIL (Fig. 7A, P ϭ 0. 
009; paired Student's t-test). The effect of BMS-345541 on WT rhTRAIL/rhTRAIL-C3 sensitivity was tested in 6 AML samples, including both rhTRAIL
Fig. 4. Pro-apoptotic potential of rhTRAIL-C3 in AML cell lines. HL-60 (A), ML-1 (B), MOLM-13 (C) and OCI-AML-3 (D) were treated with increasing doses of WT rhTRAIL, rhTRAIL-C3 and D269H/E195R for 24 hrs and induction of apoptosis was determined using annexin V assay. The graphs show the average percentage of dead cells Ϯ S.E.M. determined with flow cytometric analysis of annexin V positivity. Stars (*) indicated significant difference between connected bar pairs (P Ͻ 0.05, determined with paired t-test).
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Fig. 5. Functionality of DR4 and DR5 in AML cells. HL60 (A), ML-1 (B), MOLM-13 (C) OCI-AML3 (D) and EM-2 cells were treated with WT rhTRAIL, agonistic anti-DR4 and anti-DR5 antibodies for 24 hrs with or without previous crosslinking of the antibodies. Induction of cell death, as a measure of receptor functionality, was measured with 7-aminoactinomycin D staining and flow cytometric analysis. Graphs demonstrate the average percentage of dead cells (ϮS.E.M.) from three independent experiments.
Fig. 6. rhTRAIL-C3 activates DR4 more efficiently than WT rhTRAIL. The kinetics of receptor activation was measured by determining (A) pro-caspase-8 cleavage (B) IB phosphorylation and degradation by Western blot analysis, or (C) apoptosis induction with TMRE staining. HL-60 cells were treated with 100 ng/ml of WT rhTRAIL or rhTRAIL-C3 for the times indicated, after which it was removed from the cells and the cells washed. To detect induction of apoptosis after washing the ligands out, the cells were resuspended in normal growth medium and incubated further for 12 hrs in total. The graph shows induction of apoptosis relative to maximum apoptosis observed at 12 hrs (100%). ␤-actin was used in the Western blot analyses as a protein loading control.
sensitive and resistant samples (Fig. 7B, samples 10, 11, 14, 15 and samples 1, 9, respectively) . The response of the individual AML samples ranged from no sensitization (samples 11, 14) through additive effect (samples 1, 9, 10) to even synergistic effect (sample 15) to both WT rhTRAIL and rhTRAIL-C3. Additionally, the combination of rhTRAIL-C3 with BMS-345541 resulted in a stronger cytotoxic effect than WT rhTRAIL (Fig. 7C,  P ϭ 
for 5 M BMS-345541 ϩ WT rhTRAIL and 5 M BMS-345541 ϩ WT rhTRAIL).
While rhTRAIL-C3 showed high activity on primary AML cells, it was not toxic to non-transformed, normal cells ( Fig. 7D and E) . Human primary dermal fibroblasts as an abundant somatic cell type were tested for sensitivity to rhTRAIL-C3. Additionally, NHEK were also tested as keratinocytes have been reported to be sensitive to rhTRAIL-induced apoptosis [36] . In line with the literature, NHEK cells showed a low level of sensitivity to WT rhTRAIL (Fig. 7E) . rhTRAIL-C3 did not induce any cell death in fibroblasts and did not induce significantly more cell death than WT rhTRAIL in keratinocytes (Fig. 7D and E) .
Discussion
TRAIL is a promising anti-cancer agent as it selectively induces apoptosis in cancer cells while leaving normal cells unharmed.
However, some tumour types, such as AML, are relatively insensitive to TRAIL-induced apoptosis [37] [38] [39] [40] .
In AML blasts, despite the fact that approximately 50% of AMLs express at least one death-inducing TRAIL receptor on the cell surface, TRAIL fails to activate pro-caspase-8, indicating that inadequate receptor activation by TRAIL contributes to the low sensitivity [17] . Using agonistic antibodies specific to DR4 or DR5, we found that similar to some other leukemic cell types, such as CLL [12] 
